Cognición y modelos predictivos de calidad de vida en enfermedades neurológicas

Oteo JA, Corominas H, Escudero R, Farinas Guerrero F, Garcia Monco JC, Goenaga MA, et al. Executive summary of the consensus statement of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), Spanish Society of Neurology (SEN), Spanish Society of Immunology (SEI), Spanish Society of Pediatric Infectology (SEIP), Spanish Society of Rheumatology (SER), and Spanish Academy of Dermatology and Venereology (AEDV), on the diagnosis, treatment and prevention of Lyme borreliosis. Enferm Infecc Microbiol Clin (Engl Ed). 2023; 41(1): 40-45. DOI:10.1016/j.eimce.2022.11.011.

de la Maza SS, Gómez Ballesteros R, Borges M, Martín Martínez J, Sotoca J, Alonso A, et al. Detecting disability using self-reported and clinical assessments in early-stage relapsing-remitting multiple sclerosis: Looking for a complementary approach. Mult Scler J Exp Transl Clin. 2023; 9(2). DOI:10.1177/20552173231169475.

Daruwalla C, Shaygannejad V, Ozakbas S, Havrdova EK, Horakova D, Alroughani R, et al. Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis. Mult Scler J. 2023; 29(7): 875-883. DOI:10.1177/13524585231151951.

Diouf I, Malpas CB, Sharmin S, Roos I, Horakova D, Havrdova EK, et al. Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis. Eur J Neurol. 2023; 30(4): 1014-1024. DOI:10.1111/ene.15706.

Harding Forrester S, Roos I, Ngvyen A, Malpas CB, Diouf I, Moradi N, et al. Disability accrual in primary and secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 2023; 94(9): 707-717. DOI:10.1136/jnnp-2022-330726.

Spelman T, Ozakbas S, Alroughani R, Terzi M, Hodgkinson S, Laureys G, et al. A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registry. Neurodegener Dis Manag. 2023; 13(4): 215-221. DOI:10.2217/nmt-2023-0005.

de la Maza SS, Maurino J, Castillo Triviño T, Borges M, Torres BS, Sotoca J, et al. Hopelessness in Patients with Early-Stage Sclerosis. Patient Prefer Adherence. 2023; 17: 1431-1439. DOI:10.2147/PPA.S411069.

Diouf I, Malpas CB, Sharmin S, Roos I, Horakova D, Kubala Havrdova E, et al. Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial. J Neurol Neurosurg Psychiatry. 2023. DOI:10.1136/jnnp-2023-331499.

Obach V, Velasco F, Escudero RA, Bujanda MM, Aranceta S, Fabregat N, et al. Long-term effectiveness and tolerability of galcanezumab in patients with migraine excluded from clinical trials: real world evidence of 1055 patients with 1 year follow-up from the Galca-Only registry. J Headache Pain. 2023; 24(1). DOI:10.1186/s10194-023-01690-2.

De Brouwer E, Becker T, Moreau Y, Havrdova EK, Trojano M, Eichau S, et al. Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression (vol 208, 106180, 2021). Comput Meth Programs Biomed. 2022; 213. DOI:10.1016/j.cmpb.2021.106479.

Armenteros PR, Kapetanovic S, Lopez SG, Vazquez Lorenzo E, Mendez LA, Muga JJG, et al. Pearls & Oy-sters: Arteriovenous Malformation With Sinus Thrombosis and Thalamic Hemorrhage Unusual Cause of Parkinsonism and Dementia. Neurology. 2022; 98(13): 550-553. DOI:10.1212/WNL.0000000000200016.

Butzkueven H, Spelman T, Ozakbas S, Alroughani R, Terzi M, Hodgkinson S, et al. Real-World Comparative Effectiveness and Persistence of Cladribine Tablets and Other Oral Disease-Modifying Treatments for Multiple Sclerosis from GLIMPSE: Results from the MSBase Registry. Mult Scler J. 2022; 28(1_SUPPL): 176-177

Sanchez Luengos I, Lucas Jimenez O, Ojeda N, Pena J, Carlos Gomez Esteban J, Angeles Gomez Beldarrain M, et al. Predictors of health-related quality of life in Parkinson's disease: the impact of overlap between health-related quality of life and clinical measures. Qual Life Res. 2022; 31(11): 3241-3252. DOI:10.1007/s11136-022-03187-y.

Toca AB, Zarraga IS, Soberon SF, Picon RV, Brochado AP, Beldarrain MG. See it to believe it. Eur J Neurol. 2022; 29: 382-382

de la Maza SS, Gomez Ballesteros R, Borges M, Martin Martinez J, Sotoca J, Alonso A, et al. Self-reported and clinician-rated measures in multiple sclerosis care: looking for a complementary assessment approach. Eur J Neurol. 2022; 29: 464-465

Saposnik G, Gomez Ballesteros R, Borges M, Martin Martinez J, Sotoca J, Alonso A, et al. Processing speed in early-stage relapsing-remitting multiple sclerosis and its influence on treatment decision making. Eur J Neurol. 2022; 29: 206-206

Rodriguez SS, Gomez Muga JJ, Onandi RR, Gallarreta ZD, Garcia Monco JC. A 57-year-old man with painful ophthalmoplegia and cavernous sinus involvement: Why this is not Tolosa-Hunt syndrome. Eur J Neurol. 2022; 29(10): 3127-3129. DOI:10.1111/ene.15426.

Brochado AP, Muras AC, Oyarzun Irazu I, Rodriguez Sainz A, Caballero Romero I, Aguilera Irazabal B, et al. Drip and ship and mothership models of mechanical thrombectomy result in similar outcomes in acute ischemic stroke of the anterior circulation. J Stroke Cerebrovasc Dis. 2022; 31(10): 106733-106733. DOI:10.1016/j.jstrokecerebrovasdis.2022.106733.

Signori A, Lorscheider J, Vukusic S, Trojano M, Iaffaldano P, Hillert J, et al. Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data network. J Neurol Neurosurg Psychiatry. 2022; 94(1): 23-30. DOI:10.1136/jnnp-2022-329987.

Spelman T, Ozakbas S, Alroughani R, Terzi M, Hodgkinson S, Laureys G, et al. Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry. Mult Scler J. 2022. DOI:10.1177/13524585221137502.

Rodrigo Armenteros P, Uterga Valiente JM, Zabala Arco J, Taramundi Argueso S, Anton Mendez L, Gomez Muga JJ et al. Optic neuropathy in a patient with COVID-19 infection. Acta Neurol Belg. 2021; 122(3): 789-791. DOI:10.1007/s13760-021-01600-w.

Erburu Iriarte M, Rodrigo Armenteros P, Oyarzun Irazu I, Aranzabal Alustiza I, Silvarrey Rodriguez S, Anton Mendez L et al. Chronic severe methanol intoxication after repeated mask cleansing for fear to COVID-19 - a new risk of coronaphobia. Eur J Neurol. 2021; 28(10): 3448-3451. DOI:10.1111/ene.14779.

García Azorín D, Abildúa M, Aguirre M, Fernández SF, Moncó JCG, Guijarro Castro C et al. Neurological presentations of COVID-19: Findings from the Spanish Society of Neurology neuroCOVID-19 registry. J Neurol Sci. 2021; 423: 117283-117283. DOI:10.1016/j.jns.2020.117283.

Garcia Monco JC, Cabrera Muras A, Erburu Iriarte M, Rodrigo Armenteros P, Collia Fernandez A, Arranz Martinez J et al. Neurologic Manifestations in a Prospective Unselected Series of Hospitalized Patients With COVID-19. Neurol-Clin Pract. 2021; 11(2): 64-72. DOI:10.1212/CPJ.0000000000000913.

Fernandez AC, Anton BH, Garcia Monco JC. Progressive Ataxia and Downbeat Nystagmus in the Adult C. Magnesium depletion. JAMA Neurol. 2021; 78(8): 1018-1019. DOI:10.1001/jamaneurol.2021.1205.

De Brouwer E, Becker T, Moreau Y, Havrdova EK, Trojano M, Eichau S et al. Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression. Comput Meth Programs Biomed. 2021; 208: 106180-106180. DOI:10.1016/j.cmpb.2021.106180.

Guasp M, Landa J, Martinez Hernandez E, Sabater L, Iizuka T, Simabukuro M et al. Thymoma and Autoimmune Encephalitis: Clinical Manifestations and Antibodies. Neurol-Neuroimmunol Neuroinflammation. 2021; 8(5). DOI:10.1212/NXI.0000000000001053.

Gaig C, Compta Y, Heidbreder A, Marti MJ, Titulaer MJ, Crijnen Y et al. Frequency and Characterization of Movement Disorders in Anti-IgLON5 Disease. Neurology. 2021; 97(14): 1367-1381. DOI:10.1212/WNL.0000000000012639.

Butzkueven H, Spelman T, Ozakbas S, Boz C, Buzzard K, Skibina O et al. Real-world experience with ocrelizumab in relapsing multiple sclerosis: insights from the MSOCR-R cohort, an MSBase registry sub-study. Mult Scler J. 2021; 27(2_SUPPL): 104-106

Butzkueven H, Spelman T, Hodgkinson S, Madueno SE, Izquierdo G, Buzzard K et al. Real-world experience with cladribine in the MSBase Registry. Mult Scler J. 2021; 27(2_SUPPL): 681-683

Castillo Trivino T, Carrascal DP, Iniguez AE, Martinez MO, Martinez LM, Arruti M et al. Efficacy and safety of alemtuzumab in clinical practice in Northeastern Spain. Mult Scler J. 2021; 27(2_SUPPL): 717-718

Roos I, Sharmin S, Ozakbas S, Horakova D, Havrdova EK, Boz C et al. Comparison of the effectiveness of ocrelizumab vs interferons, fingolimod and natalizumab on relapses in relapsing-remitting multiple sclerosis. Mult Scler J. 2021; 27(2_SUPPL): 778-780

Muras AC, Irazabal BA, Sanchez JG, Romero IC, Deza E, Gonzalez AB et al. Topic: AS01 Acute Stroke Therapy, Management and Prehospital Care MECHANICAL THROMBECTOMY FOR ACUTE MIDDLE CEREBRAL ARTERY M2 SEGMENT OCCLUSION. EXPERIENCE AND RESULTS IN A TERTIARY CENTER. Int J Stroke. 2021; 16(2_SUPPL): 83-83

Diez Cirarda M, Gabilondo I, Ibarretxe Bilbao N, Gomez Esteban JC, Kim J, Lucas Jimenez O et al. Contributions of sex, depression, and cognition on brain connectivity dynamics in Parkinson's disease. npj Parkinsons Dis. 2021; 7(1). DOI:10.1038/s41531-021-00257-9.

Mena J, Alloza I, Tulloch Navarro R, Aldekoa A, Díez García J, Villanueva Etxebarria A et al. Genomic Multiple Sclerosis Risk Variants Modulate the Expression of the ANKRD55-IL6ST Gene Region in Immature Dendritic Cells. Front Immunol. 2021; 12: 816930-816930. DOI:10.3389/fimmu.2021.816930.

Harding Forrester S, Roos I, Sharmin S, Diouf I, Malpas C, Nguyen AL et al. Disability Accrual in Primary Progressive & Secondary Progressive Multiple Sclerosis. Neurology. 2021; 96(15)

Diouf I, Malpas C, Horakova D, Havrdova E, Patti F, Shaygannejad V et al. Variability of the Response to Immunotherapy Among Sub-groups of Patients With Multiple Sclerosis. Neurology. 2021; 96(15)

Dominguez Gonzalez C, Mroczek M, Kapetanovic S, AlSaman A, Gogoi R, Charlton R et al. Novel diagnostic index test CATCH2 improves detection of acute vestibular stroke (EMVERT study). Eur J Neurol. 2021; 28: 89-89

Dominguez Gonzalez C, Mroczek M, Kapetanovic S, AlSaman A, Gogoi R, Charlton R et al. Biallelic variants in the molecular chaperone DNAJB4 are a genetic cause of myopathy with respiratory muscle involvement. Eur J Neurol. 2021; 28: 90-90

Costa JV, Monica P, Nascimento A, Kapetanovic S, Moreno A, Hervas D et al. Nusinersen treatment in adult patients with 5q spinal muscular atrophy. Eur J Neurol. 2021; 28: 832-832

Vitkova M, Diouf I, Malpas C, Horakova D, Havrdova EK, Patti F et al. Association of Latitude and Exposure to Ultraviolet B Radiation with Severity of Multiple Sclerosis. Neurology. 2021; 96(15)

Toca AB, Arroyo AM, Sainz AR, Martinez JA, Zarraga IS, Calle IA et al. Mutations in MME gene causing distal hereditary motor neuropathy and MCI-AD. J Neurol Sci. 2021; 429: 92-92. DOI:10.1016/j.jns.2021.118990.

Le M, Malpas C, Sharmin S, Horakova D, Havrdova E, Trojano M, et al. Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis. Mult Scler J. 2020; 27(5): 755-766. DOI:10.1177/1352458520926955.

Diez Cirarda M, Gabilondo I, Ibarretxe Bilbao N, Gomez Esteban J, Kim J, Lucas Jimenez O, et al. Intrinsic Brain Functional Network Dynamics in Parkinson's Disease Patients with Depression. Neurology. 2020; 94(15)

Zahia S, Garcia Zapirain B, Saralegui I, Fernandez Ruanova B. Dyslexia detection using 3D convolutional neural networks and functional magnetic resonance imaging. Comput Meth Programs Biomed. 2020; 197: 105726-105726. DOI:10.1016/j.cmpb.2020.105726.

Garcia Monco JC, Cabrera Muras A, Collia Fernandez A, Erburu Iriarte M, Rodrigo Armenteros P, Oyarzun Irazu I, et al. Neurological reasons for consultation and hospitalization during the COVID-19 pandemic. Neurol Sci. 2020; 41(11): 3031-3038. DOI:10.1007/s10072-020-04714-w.

Collia Fernandez A, Garcia Sanchez JM, Rivera Perez de Rada P, Fernandez Avellaneda P, Rodrigo Armenteros P, Torre Salaberri I, et al. Recurrent Vertebrobasilar Strokes Associated With Acute Posterior Multifocal Placoid Pigment Epitheliopathy (APMPPE). Neurologist. 2020; 25(5): 131-136. DOI:10.1097/NRL.0000000000000273.

Perez M, Amayra I, Lazaro E, Garcia M, Martinez O, Caballero P, et al. Intrusion errors during verbal fluency task in amyotrophic lateral sclerosis. PLoS One. 2020; 15(5). DOI:10.1371/journal.pone.0233349.

Rodrigo Armenteros P, Uterga Valiente JM, Zabala Arco J, Taramundi Argueso S, Erburu Iriarte M, Anton Mendez L, et al. Non-convulsive status epilepticus in a patient with COVID-19 infection. Clin Neurophysiol. 2020; 131(11): 2588-2590. DOI:10.1016/j.clinph.2020.08.005.

Kunchok A, Lechner Scott J, Granella F, Trojano M, Alroughani R, Sola P, et al. Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score. Mult Scler J. 2020; 27(5): 695-705. DOI:10.1177/1352458520936823.

Cabrera Muras A, Carmona Abellan MM, Collia Fernandez A, Uterga Valiente JM, Anton Mendez L, Garcia Monco JC. Bilateral Facial Nerve Palsy associated with COVID-19 and Epstein-Barr Virus co-infection. Eur J Neurol. 2020; 28(1): 358-360. DOI:10.1111/ene.14561.

Diez Cirarda M, Gabilondo I, Ibarretxe Bilbao N, Gomez Esteban JC, Kim J, Lucas Jimenez O, et al. Sex differences on dynamic functional connectivity in Parkinson's disease and healthy controls. Mov Disord. 2020; 35: 242-243

Diouf I, Malpas C, Horakova D, Havrdova EK, Patti F, Shaygannejad V, et al. Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis. Mult Scler J. 2020; 26(3_SUPPL): 126-127

Harding Forrester S, Roos I, Sharmin S, Diouf I, Malpas C, Nguyen AL, et al. Disability accrual in primary-progressive & secondary-progressive multiple sclerosis. Mult Scler J. 2020; 26(3_SUPPL): 527-528

Butzkueven H, Spelman T, Ozakbas S, Kalincik T, Boz C, Buzzard K, et al. Real-world experience with ocrelizumab in the msbase registry. Mult Scler J. 2020; 26(3_SUPPL): 550-551

Kalincik T, Diouf I, Sharmin S, Malpas C, Spelman T, Horakova D, et al. Effect of Disease Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years. Neurology. 2020; 96(5): 783-797. DOI:10.1212/WNL.0000000000011242.

Pinedo Brochado A, Vidorreta Ballesteros L, Arranz Martinez JJ, Sustacha Zarraga I, Barquin Toca A, Anton Ladislao A, et al. DRIP-AND-SHIP MODEL FOR STROKE TREATMENT IS VALID: TIME AND PATIENT SELECTION IS WHAT MATTERS. Int J Stroke. 2020; 15(1_SUPPL): 332-332

Pinedo Brochado A, Vidorreta Ballesteros L, Arranz Martinez JJ, Sustacha Zarraga I, Barquin Toca A, Anton Ladislao A, et al. ANTERIOR CIRCULATION FUTILE RECANALIZATION PREDICTORS IN A DRIPAND SHIP MODEL OF ISCHEMIC STROKE TREATMENT. Int J Stroke. 2020; 15(1_SUPPL): 427-427

Cabrera Muras A, Garcia Sanchez J, Collia Fernandez A, Gil Alzueta MDC, Rodrigo Armenteros P, Erburu Iriarte M, et al. MECHANICAL THROMBECTOMY IN ELDERLY PATIENTS. A COMPARATIVE STUDY IN A TERTIARY CENTER. Int J Stroke. 2020; 15(1_SUPPL): 122-122

Sustacha Zarraga I, Barquin Toca A, Vidorreta Ballesteros L, Arranz Martinez JJ, Rodriguez Sainz A, Ruisanchez Nieva A, et al. PERFUSION ABNORMALITIES ON NEUROIMAGING: MIGRAINE OR STROKE?. Int J Stroke. 2020; 15(1_SUPPL): 287-287

Collia Fernandez A, Gil Alzueta MDC, Cabrera Muras A, Sainz Pelayo A, Erburu Iriarte M, Rodrigo Armenteros P, et al. THROMBECTOMY IN STROKE WITH UNKNOWN ONSET: TWO-YEAR EXPERIENCE IN A TERCIARY CENTER. Int J Stroke. 2020; 15(1_SUPPL): 428-428

Sanchez Luengos I, Lucas Jimenez O, Pena J, Ojeda N, Gomez Esteban JC, Gomez Beldarrain MA, et al. PREDICTORS OF QUALITY OF LIFE IN PARKINSON'S DISEASE. Parkinsonism Relat Disord. 2020; 79: 18-18

Olascoaga Arrate A, Freijo Guerrero MM, Fernández Maiztegi C, Azkune Calle I, Silvariño Fernández R, Fernández Rodríguez M, et al. Use of emergency medical transport and impact on time to care in patients with ischaemic stroke. Neurologia. 2019; 34(2): 80-88. DOI:10.1016/j.nrl.2016.11.004.

Alonso Jimenez A, Kroon RHMJM, Alejaldre Monforte A, Nuñez Peralta C, Horlings CGC, van Engelen BGM, et al. Muscle MRI in a large cohort of patients with oculopharyngeal muscular dystrophy. J Neurol Neurosurg Psychiatry. 2019; 90(5): 576-585. DOI:10.1136/jnnp-2018-319578.

Nguyen AL, Havrdova EK, Horakova D, Izquierdo G, Kalincik T, van der Walt A, et al. Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study. Mult Scler Relat Disord. 2019; 28: 235-243. DOI:10.1016/j.msard.2019.01.003.

Gutiérrez G, Díaz Manera J, Almendrote M, Azriel S, Eulalio Bárcena J, Cabezudo García P, et al. Clinical guide for the diagnosis and follow-up of myotonic dystrophy type 1, MD1 or Steinert's disease. Med Clin. 2019; 153(2): 82-82. DOI:10.1016/j.medcli.2018.10.028.

Olascoaga Arrate A, Freijo Guerrero MM, Fernandez Maiztegi C, Azkune Calle I, Silvarino Fernandez R, Fernandez Rodriguez M, et al. Relacion del nivel de estudios con la supervivencia en el primer año tras un ictus isquemico. Rev Neurologia. 2019; 68(4): 147-154. DOI:10.33588/rn.6804.2018254.

Garcia Monco JC, Benach JL. Lyme Neuroborreliosis: Clinical Outcomes, Controversy, Pathogenesis, and Polymicrobial Infections. Ann Neurol. 2019; 85(1): 21-31. DOI:10.1002/ana.25389.

Castanedo Vazquez D, Bosque Varela P, Sainz Pelayo A, Riancho J. Infectious agents and amyotrophic lateral sclerosis: another piece of the puzzle of motor neuron degeneration. J Neurol. 2019; 266(1): 27-36. DOI:10.1007/s00415-018-8919-3.

Lorscheider J, Kuhle J, Izquierdo G, Lugaresi A, Havrdova E, Horakova D, et al. Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study. Eur J Neurol. 2019; 26(2): 363-370. DOI:10.1111/ene.13824.

Brown JWL, Coles A, Horakova D, Havrdova E, Izquierdo G, Prat A, et al. Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. JAMA-J Am Med Assoc. 2019; 321(2): 175-187. DOI:10.1001/jama.2018.20588.

Anguizola Tamayo D, Bocos Portillo J, Pardina Vilella L, Rodriguez Sainz A, Vicente Olabarria I, Martinez E, et al. Psychosis of dual origin in HIV infection Viral escape syndrome and autoimmune encephalitis. Neurol-Clin Pract. 2019; 9(2): 178-180. DOI:10.1212/CPJ.0000000000000582.

Kalincik T, Havrdova EK, Horakova D, Izquierdo G, Prat A, Girard M, et al. Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. J Neurol Neurosurg Psychiatry. 2019; 90(4): 458-468. DOI:10.1136/jnnp-2018-319831.

Garcia Monco JC, Sommer K, Afanador L, Franznick D, Asmus P, Becker V, et al. An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study. J Headache Pain. 2019; 20. DOI:10.1186/s10194-019-0976-1.

Rafehi H, Szmulewicz DJ, Bennett MF, Sobreira NLM, Pope K, Smith KR, et al. Bioinformatics-Based Identification of Expanded Repeats: A Non-reference Intronic Pentamer Expansion in RFC1 Causes CANVAS. Am J Hum Genet. 2019; 105(1): 151-165. DOI:10.1016/j.ajhg.2019.05.016.

Fambiatos A, Jokubaitis V, Horakova D, Kubala Havrdova E, Trojano M, Prat A, et al. Risk of secondary progressive multiple sclerosis: A longitudinal study. Mult Scler J. 2019; 26(1): 79-90. DOI:10.1177/1352458519868990.

Zhou Y, Claflin SB, Stankovich J, van der Mei I, Simpson S, Roxburgh RH, et al. Redefining the Multiple Sclerosis Severity Score (MSSS): The effect of sex and onset phenotype. Mult Scler J. 2019; 26(13): 1765-1774. DOI:10.1177/1352458519881994.

Rodrigo Armenteros P, Kapetanovic Garcia S, Anton Mendez L, Jose Gomez Muga J, Bedia Del Rio E, Angeles Fernandez Cuesta M, et al. Akinetic mutism and status epilepticus due to Epstein Barr virus encephalitis. Clin Neurol Neurosurg. 2019; 185: 105492-105492. DOI:10.1016/j.clineuro.2019.105492.

Carlos Garcia Monco J, Gonzalo Garcia A, Garcia Sanchez JM, Martinez Vazquez MM, Munoz Tena R, Olaldecoa Alonso AI, et al. The stroke pathway: an integrated approach to health care of stroke patients. Int J Integr Care. 2019; 19(1). DOI:10.5334/ijic.s3544.

Gomez Beldarrain M, Santos Ibanez A, Maldonado Fernandez MC, Martinez Bengoechea MJ, Carlos Garcia Monco J. An integrated, cost-effective efficient chain to deliver botulinum toxin in optimal conditions. Int J Integr Care. 2019; 19(1). DOI:10.5334/ijic.s3547.

De Brouwer E, Peeters L, Becker T, Altintas A, Soysal A, Van Wijmeersch B, et al. Introducing Machine Learning for full MS patient trajectories improves predictions for disability score progression. Mult Scler J. 2019; 25: 63-65

Sharmin S, Malpas C, Horakova D, Havrdova EK, Izquierdo G, Eichau S, et al. Predicting long-term sustained disability progression in multiple sclerosis. Mult Scler J. 2019; 25: 119-121

Kortazar Zubizarreta I, Pinedo Brochado A, Azkune Calle I, Aguirre Larracoechea U, Gomez Beldarrain M, Garcia Monco JC. Predictors of in-hospital mortality after ischemic stroke: A prospective, single-center study. Health Sci Rep. 2019; 2(4). DOI:10.1002/hsr2.110.

Leira Y, Pozo Rosich P, Torres Ferrús M, Orlandi M, Láinez JM, Álvaro LC, et al. Self-reported periodontitis and migraine: results from a multicenter, cross-sectional survey in Spain. Odontology. 2019; 107(4): 530-535. DOI:10.1007/s10266-019-00430-w.

Munoz SG, Salazar LM, Ocharan MI, Garcia SK, Garay RP, Gredilla F. Cerebrospinal fluid Tau protein as a marker of brain injury. Clin Chim Acta. 2019; 493: 610-610. DOI:10.1016/j.cca.2019.03.1277.

Fragoso YD, Spelman T, Boz C, Alroughani R, Lugaresi A, Vucic S, et al. Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod. Mult Scler Relat Disord. 2018; 19: 105-108. DOI:10.1016/j.msard.2017.11.018.

Diez Cirarda M, Ojeda N, Pena J, Cabrera Zubizarreta A, Lucas Jimenez O, Gomez Esteban JC, et al. Long-term effects of cognitive rehabilitation on brain, functional outcome and cognition in Parkinson's disease. Eur J Neurol. 2018; 25(1): 5-12. DOI:10.1111/ene.13472.

Signori A, Izquierdo G, Lugaresi A, Hupperts R, Grand’Maison F, Sola P, et al. Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis. Mult Scler J. 2018; 24(5): 642-652. DOI:10.1177/1352458517703800.

Fragoso YD, Spelman T, Boz C, Alroughani R, Lugaresi A, Vucic S, et al. Reply to: Comment on YD Fragoso et al.: "Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod" [Mult. Scler. Relat. Disord. (2017)]. Mult Scler Relat Disord. 2018; 22: 166-166. DOI:10.1016/j.msard.2018.02.025.

Pardina Vilella L, Pinedo Brochado A, Vicente I, Bocos Portillo J, Martínez Arroyo A, Ontañon JM, et al. The goblet sign in the amnestic syndrome of the subcallosal artery infarct. Neurol Sci. 2018; 39(8): 1463-1465. DOI:10.1007/s10072-018-3425-z.

Lucas Jimenez O, Ojeda N, Pena J, Cabrera Zubizarreta A, Diez Cirarda M, Gomez Esteban JC, et al. Apathy and brain alterations in Parkinson's disease: a multimodal imaging study. Ann Clin Transl Neurol. 2018; 5(7): 803-814. DOI:10.1002/acn3.578.

Bocos Portillo J, Escalza Cortina I, Gómez Beldarrain M, Rodriguez Sainz A, Garcia Monco JC. Unilateral or bilateral punctate hippocampal hyperintensities on DW-MRI: seizures, amnesia, or both?. Neurol Sci. 2018; 39(9): 1647-1649. DOI:10.1007/s10072-018-3461-8.

Fernández Vega I, Díaz Lucena D, Azkune Calle I, Geijo M, Juste RA, Llorens F, et al. Sporadic Creutzfeldt-Jakob disease with glial PrPRes nuclear and perinuclear immunoreactivity. Neuropathology. 2018; 38(5): 561-567. DOI:10.1111/neup.12505.

Eichau S, Spelman T, Izquierdo G, Laffaldano P, Oreja Guevara C, Butzkueven H, et al. Familial multiple sclerosis: comparing demographic and clinical characteristics with sporadic form. Mult Scler J. 2018; 24(2): 24-25

Cervantes CE, Gomez Ulloa D, Elorriaga A, Garcia JM, Freijo M, Tapias IC, et al. PRODUCTIVITY LOSS AND LOCAL INDIRECT COSTS ASSOCIATED WITH ACUTE CORONARY SYNDROME AND STROKE IN SPAIN. Value Health. 2018; 21: 102-102

Bocos Portillo J, Sánchez Menoyo JL, Beldarrain MG, Saralegui Prieto I, Ontañón Garcés JM, Dalmau J, et al. Acute disseminated encephalomyelitis: A rare autoimmune complication of herpes simplex encephalitis in the adult. Clin Neurol Neurosurg. 2018; 175: 47-49. DOI:10.1016/j.clineuro.2018.10.007.

Ahmed F, Gaul C, Martelletti P, Garcia Monco JC, Adams AM. Real-Life Use of OnabotulinumtoxinA for the Symptomatic Treatment of Chronic Migraine: The REPOSE Study. Neurology. 2018; 90(15)

Armangue T, Spatola M, Vlagea A, Mattozzi S, Cárceles Cordon M, Martinez Heras E, et al. Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis. Lancet Neurol. 2018; 17(9): 760-772. DOI:10.1016/S1474-4422(18)30244-8.

Le MVH, Malpas C, Sharmin S, Horakova D, Havrdova EK, Trojano M, et al. Disability outcomes in patients with early cerebellar symptoms in multiple sclerosis. Mult Scler J. 2018; 24: 135-137

Min M, Spelman T, Lugaresi A, Boz C, Spitaleri D, Pucci E, et al. Silent lesions on MRI imaging - Shifting goal posts for treatment decisions in multiple sclerosis. Mult Scler J. 2018; 24(12): 1569-1577. DOI:10.1177/1352458518798147.

GARCIA-MONCO CARRA JC, GOMEZ BELDARRAIN MA, PINEDO BROCHADO AC, RODRIGUEZ SAINZ A. Preventive therapy with citalopram added to a beta blocker does not result in quality-of-life improvement in patients with episodic migraine. Cephalalgia Reports. 2018. DOI:10.1177.